Ninety minutes instead of three days to know what you're fighting
As the Omicron variant moved swiftly across borders in late 2021, the gap between a virus's speed and science's ability to name it became a quiet crisis. Researchers at IIT Delhi's Kusuma School of Biological Sciences answered with an RT-PCR assay capable of identifying Omicron's distinct genetic signatures in ninety minutes — compressing what sequencing laboratories needed three days to accomplish. The innovation arrives not from an institution new to this work, but from one that has already walked the long road from laboratory discovery to national deployment, suggesting that urgency and experience may this time move together.
- Omicron's rapid global spread exposed a critical lag: standard sequencing methods took more than three days to confirm the variant, leaving public health systems flying partially blind.
- With 38 confirmed cases across multiple Indian states and the WHO designating Omicron a variant of concern, the pressure to identify infections faster was no longer hypothetical.
- IIT Delhi's team engineered an RT-PCR assay targeting mutations unique to Omicron's S gene, cutting confirmation time from days to ninety minutes using real-time PCR on synthetic DNA fragments.
- The institute filed an Indian patent application and opened talks with industry partners, aiming to convert a laboratory success into a deployable tool for hospitals and testing centers.
- IIT Delhi's credibility as India's first academic institution to earn ICMR approval for a PCR diagnostic — and its prior success reducing national COVID-19 testing costs — positions this assay as a serious candidate for rapid commercialization.
When Omicron began spreading globally in late 2021, the standard method for confirming the variant — next-generation sequencing — demanded more than three days per sample. For a fast-moving virus, that delay carried real consequences.
Researchers at IIT Delhi's Kusuma School of Biological Sciences designed a different path. Their RT-PCR assay targets specific mutations found in Omicron's S gene but absent in other circulating SARS-CoV-2 strains, using primer sets that amplify these unique markers and distinguish the new variant from the wild-type virus in just ninety minutes. The institute moved swiftly to protect the work, filing a patent application and entering early conversations with industry partners to bring the assay into clinical use.
The effort carried institutional weight. IIT Delhi had already become the first academic body in India to receive ICMR approval for a real-time PCR diagnostic, and its earlier COVID-19 testing kit had successfully reduced testing costs at a national scale — proof that the institute could navigate the distance between research and real-world deployment.
By mid-December 2021, India had confirmed 38 Omicron cases across Bengaluru, Kerala, Andhra Pradesh, Chandigarh, Maharashtra, and Karnataka, while the variant had reached roughly sixty countries worldwide. The question facing IIT Delhi's assay was no longer scientific — it was logistical: how quickly could industry partnerships scale the innovation into a standard tool as the variant continued its advance.
When the Omicron variant began spreading across the globe in late 2021, laboratories worldwide faced a familiar problem: identifying it took time. The standard method—next-generation sequencing—required more than three days to confirm whether a positive COVID-19 sample carried the new strain. For a virus moving fast, three days felt like an eternity.
Researchers at IIT Delhi saw an opportunity. Working from the Kusuma School of Biological Sciences, they designed a different approach: an RT-PCR assay that could pinpoint Omicron's telltale genetic signatures in ninety minutes. The method works by targeting specific mutations that appear in Omicron but nowhere else in the currently circulating variants of SARS-CoV-2. The team designed primer sets that amplify these unique markers in the S gene, then tested the assay using real-time PCR on synthetic DNA fragments to ensure it could reliably distinguish the new variant from the wild-type virus and other strains in circulation.
The speed advantage was substantial. Where sequencing required days, this assay needed only an hour and a half. The institute moved quickly to protect the innovation, filing an Indian patent application for the rapid screening method. Conversations with potential industry partners were already underway—the goal was to move from laboratory success to something hospitals and testing centers could actually use.
This wasn't IIT Delhi's first breakthrough in diagnostic testing. The institute had already earned distinction as the first academic institution in India to receive approval from the Indian Council of Medical Research (ICMR) for a real-time PCR-based diagnostic assay. That earlier work had focused on making COVID-19 testing affordable, significantly reducing costs and bringing testing within reach of large populations across the country. Following ICMR approval, that kit had successfully entered the market. The institute had already proven it could move from research to real-world application.
By mid-December 2021, Omicron was no longer theoretical. India had confirmed its first cases in Bengaluru, where two people tested positive. Within days, Kerala, Andhra Pradesh, and Chandigarh reported their first cases. Maharashtra and Karnataka each added one more. The national tally had climbed to thirty-eight confirmed cases. Globally, the variant had been detected in roughly sixty countries, and the World Health Organisation had classified it as a variant of concern.
The timing of IIT Delhi's assay development aligned with the moment when rapid identification mattered most. As Omicron spread, the ability to confirm cases in ninety minutes rather than three days could reshape how quickly public health systems could respond—isolating cases faster, tracing contacts sooner, understanding the variant's movement through populations in real time. The institute's track record suggested the assay would eventually reach clinics and labs. What remained to be seen was how quickly industry partnerships could scale the innovation and whether it would become a standard tool in India's testing infrastructure as the variant continued its global advance.
Citações Notáveis
The assay targets specific mutations present in Omicron and absent in other circulating variants, using primer sets designed for real-time PCR amplification— IIT Delhi official
Using this RT-PCR based assay, it will be possible to test for the presence of the Omicron variant within 90 minutes— IIT Delhi official
A Conversa do Hearth Outra perspectiva sobre a história
Why does ninety minutes matter so much when we're talking about a virus that's already spreading?
Because in those missing two and a half days, an infected person keeps moving through their life—going to work, seeing family, taking transit. If you can confirm Omicron in ninety minutes instead of three days, you can isolate them while the window for transmission is still narrow.
But this is just one test. How does it change the actual response?
It doesn't change everything, but it changes the speed of knowing. Right now, if someone tests positive, labs don't know if it's Omicron or Delta or something else for days. With this assay, you know in ninety minutes. That lets hospitals and public health officials make decisions faster—whether to escalate precautions, whether to alert contacts immediately.
IIT Delhi has done this before with COVID testing costs. Why should we believe this will actually reach people?
They have the ICMR approval already, which is the regulatory hurdle. They've already commercialized one assay successfully. They're talking to industry partners now. The infrastructure exists. The question is whether the market moves fast enough.
What's the real limitation here?
Scaling. A brilliant assay in a lab is still just a lab result. You need manufacturers to produce kits, hospitals to adopt them, technicians trained to run them. That takes months, sometimes longer. By then, Omicron might already be everywhere.
So this is a race against time.
It always is with variants. The faster you can identify them, the faster you can respond. But "faster" in a lab and "faster" in the real world are two different things.